Skip to main content
Clinical Trials/NCT03422614
NCT03422614
Recruiting
Not Applicable

Pathophysiologie Angeborener Immundefekte

University of Zurich1 site in 1 country300 target enrollmentJuly 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Immune Deficiency Disorder
Sponsor
University of Zurich
Enrollment
300
Locations
1
Primary Endpoint
Characterisation of cellular phenotype in different PIDs
Status
Recruiting
Last Updated
8 years ago

Overview

Brief Summary

The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and/or a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.

Registry
clinicaltrials.gov
Start Date
July 1, 2015
End Date
July 1, 2025
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Janine Reichenbach

Co-Head Division Immunology

University of Zurich

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)
  • Clinically healthy (non-age matched) volunteer

Exclusion Criteria

  • exclusion of an inborn error of immunity
  • secondary immunodeficiency
  • refusal to enter the study

Outcomes

Primary Outcomes

Characterisation of cellular phenotype in different PIDs

Time Frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples

Immune cell subsets will be analysed for Surface marker Expression or cell activation pathways

Characterisation of functional phenotype in different PIDs

Time Frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples

Immune cell subsets will be analysed for cytokine production or cell activation pathways

Secondary Outcomes

  • Identification of potential targets for pathophysiology-specific treatment, or for curative treatment such as gene therapy for different PIDs ex vivo(immediately after sampling of biological specimen or up to 10 years later from frozen samples)

Study Sites (1)

Loading locations...

Similar Trials